Venlafaxine withdrawal syndrome not prevented by maprotiline, but resolved by sertraline.
Luckhaus
C
C
Jacob
C
C
D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D003511:Cyclohexanols / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008376:Maprotiline / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline / Q000627:therapeutic use*; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D008376:Maprotiline; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D000069470:Venlafaxine Hydrochloride